TriSalus Life Sciences (TLSI) Net Equity Issued and Repurchased (2024 - 2026)

TriSalus Life Sciences' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $42.6 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $42.6 million in Q1 2026; TTM through Mar 2026 was $64.6 million, a 440.21% increase from a year earlier, with the FY2025 full-year figure at $22.0 million, up 45.66% from the prior year.
• Net Equity Issued and Repurchased rose to $42.6 million in Q1 2026 per TLSI's latest filing, from -$211000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $42.6 million in Q1 2026 and bottomed at -$211000.0 in Q4 2025.
• The 3-year median for Net Equity Issued and Repurchased is $3.6 million (2024), against an average of $11.4 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 516.63% in 2025; the steepest drop was 108.38% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at $2.5 million in 2024, then tumbled by 108.38% to -$211000.0 in 2025, then jumped by 20301.42% to $42.6 million in 2026.
• Per Business Quant, the three latest TLSI Net Equity Issued and Repurchased figures stand at $42.6 million (Q1 2026), -$211000.0 (Q4 2025), and $22.2 million (Q2 2025).